Position
BARCLAYS PLC in Arbutus Biopharma Corp
Back to the book · All holders of ABUS
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$110.6K$4.81 → $4.50
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2022 | 30.5K | $71.1K | — | — | — | 0.0% |
| Q1 2023 | 57.6K | $174.4K | $3.03 | $21.4K | $82K | 0.0% |
| Q2 2023 | 47.9K | $110.2K | $2.30 | −$35K | −$29.3K | 0.0% |
| Q3 2023 | 131.8K | $267.6K | $2.03 | −$12.9K | $170.4K | 0.0% |
| Q4 2023 | 215.9K | $539.9K | $2.50 | $62K | $210.2K | 0.0% |
| Q1 2024 | 89.2K | $230.1K | $2.58 | $7.14K | −$316.9K | 0.0% |
| Q2 2024 | 48K | $148.4K | $3.09 | $24.5K | −$106.2K | 0.0% |
| Q3 2024 | 272K | $1.05M | $3.85 | $36.5K | $862.4K | 0.0% |
| Q4 2024 | 298.3K | $975.3K | $3.27 | −$157.8K | $85.8K | 0.0% |
| Q1 2025 | 226.2K | $789.3K | $3.49 | $49.8K | −$235.7K | 0.0% |
| Q2 2025 | 406.6K | $1.26M | $3.09 | −$90.5K | $557.4K | 0.0% |
| Q3 2025 | 284.3K | $1.29M | $4.54 | $412.3K | −$377.7K | 0.0% |
| Q4 2025 | 356.7K | $1.72M | $4.81 | $76.8K | $348K | 0.0% |
| Q1 2026 | 4.32M | $19.4M | $4.50 | −$110.6K | $17.8M | 0.0% |